Although these subtypes are not being used to direct treatment decisions for SCLC at present, we expect that POU2F3 and/or YAP1 SCLC subtypes could be better targeted with a combination of DT2216 and an mTOR inhibitor. This evidence concerns the gene YAP1 and small cell lung carcinoma.